Compare VRAR & CALC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VRAR | CALC |
|---|---|---|
| Founded | 2016 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 21.9M | 63.0M |
| IPO Year | 2021 | N/A |
| Metric | VRAR | CALC |
|---|---|---|
| Price | $1.03 | $4.40 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | $2.62 | ★ $14.50 |
| AVG Volume (30 Days) | 96.7K | ★ 118.8K |
| Earning Date | 11-13-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $9,488,209.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $72.00 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 16.60 | N/A |
| 52 Week Low | $0.96 | $1.42 |
| 52 Week High | $7.00 | $4.82 |
| Indicator | VRAR | CALC |
|---|---|---|
| Relative Strength Index (RSI) | 38.07 | 59.59 |
| Support Level | $1.03 | $4.09 |
| Resistance Level | $1.16 | $4.75 |
| Average True Range (ATR) | 0.08 | 0.45 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 0.00 | 69.97 |
The Glimpse Group Inc is a diversified immersive technology platform company, focused on providing enterprise solutions in virtual reality (VR), augmented reality (AR), and spatial computing. The company operates multiple subsidiaries that develop VR and AR software and services across various industries, including corporate training, education, healthcare, government, defense, marketing, retail, and financial services. It also offers AI-driven spatial computing platforms that support simulations, social VR, behavioral health, and corporate events. The Company reports its revenues in three categories: Software Services, Software License and Software-as-a-Service (SaaS), and Royalty Income, with the majority being from the Software Services category.
CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys.